Abstract A179: NMS-P113, a novel orally available JAK2 selective inhibitor
Paola Gnocchi(Mario Negri Institute for Pharmacological Research), Arturo Galvani(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Simona Bindi(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Maria Gabriella Brasca(Nerviano Medical Sciences), Cinzia Pellizzoni(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Giulia Canevari(Nerviano Medical Sciences), M. Nesi(Nerviano Medical Sciences), Elena Ardini(Nerviano Medical Sciences), Eduard Felder, Daniele Casero(Nerviano Medical Sciences), Cinzia Cristiani(Politecnico di Milano), Veronica Patton(University of L'Aquila), Sabrina Cribioli(Nerviano Medical Sciences), Roberta Ceruti(Nerviano Medical Sciences), Gemma Texidó(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 0
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury
|Cell Death and Disease|2015|129